<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-144392" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Mild Cognitive Impairment</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Anand</surname>
            <given-names>Shruti</given-names>
          </name>
          <aff>Cleveland Clinic Foundation, Cleveland, OH</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Schoo</surname>
            <given-names>Caroline</given-names>
          </name>
          <aff>VOA PACE</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Shruti Anand declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Caroline Schoo declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>11</day>
          <month>1</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-144392.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Memory loss is a common complaint among older adults, and cognitive decline can present in various ways. It&#x000a0;is a part of the normal aging process, subjective cognitive impairment (symptomatic complaints with normal neurocognitive test results), mild cognitive impairment, or dementia.<xref ref-type="bibr" rid="article-144392.r1">[1]</xref>&#x000a0;Although mild cognitive impairment (MCI) has been used in the literature since the 1960s, it was first fully characterized in 1997 by Petersen and colleagues at the Mayo Clinic. As part of their community aging study, they observed individuals with memory concerns beyond what was expected for their age. They demonstrated memory impairment on objective testing yet did not fulfill the criteria for dementia.<xref ref-type="bibr" rid="article-144392.r2">[2]</xref>&#x000a0;MCI was&#x000a0;deemed to represent a borderline between normal aging and very early dementia. The earlier criteria for MCI diagnosis were found inadequate when it was realized that not all patients with MCI progressed to dementia and that memory impairment was not the only cognitive domain affected.<xref ref-type="bibr" rid="article-144392.r2">[2]</xref>&#x000a0;Thus, a broader definition of MCI was needed. In 2003, the first Key Symposium on MCI was held, leading to the publication of revised core clinical criteria.<xref ref-type="bibr" rid="article-144392.r3">[3]</xref>&#x000a0;These criteria included cognitive complaints from the patient or family members, deficits in any cognitive domain and not only memory, preserved overall general function but&#x000a0;increasing&#x000a0;difficulties in activities of daily life, and no dementia.<xref ref-type="bibr" rid="article-144392.r4">[4]</xref>&#x000a0;The concept of MCI traveled outside the realm of research to provide clinicians with a useful diagnosis, often for close monitoring. Further clinical research resulted in the development of novel clinical criteria for providers.&#x000a0;</p>
        <p>The American Psychiatry Association's Diagnostic and Statistical Manual of Mental Disorders 5th Edition (DSM-V) in 2013 classified MCI as one of the neurocognitive disorders (NCD). It is characterized by a decline in one or more cognitive domains, which is both subjectively and objectively observable. However, this decline does not interfere with the individual's ability to perform daily activities independently. Moreover, the deficits cannot be attributed to delirium or other psychiatric conditions.<xref ref-type="bibr" rid="article-144392.r4">[4]</xref>&#x000a0;DSM-V does not propose specific neuropsychology test scores for diagnosing mild NCD. However, it is implied that such scores would help make this diagnosis. After diagnosing the syndrome as mild NCD, the next step&#x000a0;is determining the etiology.<xref ref-type="bibr" rid="article-144392.r3">[3]</xref>&#x000a0;The 11th Revision of the International Classification of Diseases (ICD 11) by the World Health Organization (WHO) in 2018 adopted the definition of mild neurocognitive disorder in alignment with the DSM-V diagnostic criteria.<xref ref-type="bibr" rid="article-144392.r4">[4]</xref></p>
        <p>The National Institute on Aging and the Alzheimer's Association (NIA-AA) convened a work group to discuss the MCI criteria. The group proposed metrics for the distinct definition of MCI due to Alzheimer Disease. The initial criteria were published in 2011 and revised in 2018. The initial criteria closely resemble the core clinical criteria proposed by the 2003 Symposium. The 2018 revision noted that neurobehavioral disturbance may be an important feature of the clinical presentation and that cognitive deficits may result in a mild but noticeable impact on the complex activities of daily living.<xref ref-type="bibr" rid="article-144392.r4">[4]</xref>&#x000a0;The NIA-AA also suggested research criteria for MCI due to AD in 2011 to help determine the etiology of MCI established by the core clinical criteria. These included the use of biomarkers to differentiate MCI due to AD from MCI due to other reasons. The biomarkers are not used to define MCI but can be helpful in research settings. The two main helpful biomarkers are amyloid-beta (A&#x003b2;) deposition and neuronal injury.<xref ref-type="bibr" rid="article-144392.r5">[5]</xref><xref ref-type="bibr" rid="article-144392.r3">[3]</xref></p>
        <p>MCI can also be classified based on the type of cognitive domain that is affected. MCI can potentially affect one or more of the following 6 cognitive domains: learning and memory, language, complex attention, executive function, social cognition, and visuospatial function.<xref ref-type="bibr" rid="article-144392.r6">[6]</xref>&#x000a0;MCI can be classified as "amnestic" or "non-amnestic" with deficits in single or multiple cognitive domains. Amnestic MCI presents with predominant memory loss and the risk for progression to Alzheimer's Disease. In non-amnestic MCI, memory is relatively intact, and it is less common than the amnestic type and may progress to non-Alzheimer disease dementia.<xref ref-type="bibr" rid="article-144392.r6">[6]</xref><xref ref-type="bibr" rid="article-144392.r4">[4]</xref>&#x000a0;MCI can be further categorized into&#x000a0;4 subtypes:<xref ref-type="bibr" rid="article-144392.r2">[2]</xref><xref ref-type="bibr" rid="article-144392.r1">[1]</xref>&#x000a0;</p>
        <table-wrap id="article-144392.table0" position="float" orientation="portrait">
          <table style="width: 763.359px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr>
                <td style="width: 253px;" rowspan="1" colspan="1">&#x000a0;Amnestic MCI (a- MCI) single domain&#x000a0;</td>
                <td style="width: 383.359px;" rowspan="1" colspan="1">&#x000a0;Isolated impairment in memory&#x000a0;</td>
              </tr>
              <tr>
                <td style="width: 253px;" rowspan="1" colspan="1">&#x000a0;Amnestic MCI (a-MCI) multiple domain&#x000a0;&#x000a0;</td>
                <td style="width: 383.359px;" rowspan="1" colspan="1">&#x000a0;Impairment in memory AND one or more other domains&#x000a0;</td>
              </tr>
              <tr>
                <td style="width: 253px;" rowspan="1" colspan="1">
<p>&#x000a0;Non-amnestic MCI (na-MCI) single domain&#x000a0;&#x000a0;</p>
</td>
                <td style="width: 383.359px;" rowspan="1" colspan="1">&#x000a0;Impairment in only one cognitive domain with intact memory&#x000a0;</td>
              </tr>
              <tr>
                <td style="width: 253px;" rowspan="1" colspan="1">&#x000a0;Non-amnestic MCI (na- MCI) multiple domain&#x000a0;</td>
                <td style="width: 383.359px;" rowspan="1" colspan="1">&#x000a0;Impairment in more than one cognitive domain with intact memory&#x000a0;</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>In 2009, a comprehensive Neuropsychology classification system was introduced as the dichotomous classification was considered inadequate to represent the heterogeneous nature of MCI.<xref ref-type="bibr" rid="article-144392.r7">[7]</xref>&#x000a0;These MCI classes are:&#x000a0;</p>
        <list list-type="order">
          <list-item>
            <p>Amnestic - impaired recall and recognition&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Mixed - impairments in various domains such as language, executive function, recall and recognition, and visuospatial functioning.</p>
          </list-item>
          <list-item>
            <p>Dysexecutive - impairments in attention, executive, and visuospatial functions, but the memory remains intact.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Visuospatial - impairment in only a single measure of visual construction.&#x000a0;</p>
          </list-item>
        </list>
        <p>The phenotypic classification of MCI with clinical information and laboratory tests can guide the clinician in determining the probable cause of MCI and predicting its course. Patients with dysexecutive MCI (dMCI) are less likely to have Alzheimer - type dementia and more likely to have a stroke.<xref ref-type="bibr" rid="article-144392.r7">[7]</xref></p>
      </sec>
      <sec id="article-144392.s2" sec-type="Etiology">
        <title>Etiology</title>
        <p>There are various risk factors for MCI.&#x000a0;</p>
        <p><bold>Non-Modifiable Risk Factors</bold>&#x000a0;</p>
        <p>Advancing age is the strongest risk factor for MCI. Other risk factors include male sex, family history of cognitive impairment, and the presence of the apolipoprotein E (APOE) allele.<xref ref-type="bibr" rid="article-144392.r6">[6]</xref>&#x000a0;The APOE&#x000a0;&#x003b5;4 allele is the most frequent genetic risk factor associated with the progression of MCI to Alzheimer dementia. Some studies have reported an increased risk of progression to Alzheimer dementia in both carriers and homozygotes for APOE&#x000a0;&#x003b5;4 allele, while other studies have not found any association. Hence, the clinical utility of using the APOE genotype is limited.<xref ref-type="bibr" rid="article-144392.r8">[8]</xref></p>
        <p>
<bold>Modifiable or Reversible Risk Factors&#x000a0;</bold>
</p>
        <p>
<bold>Chronic Medical Conditions and Multimorbidity</bold>
</p>
        <p>Vascular risk factors such as hypertension, hyperlipidemia, coronary artery disease, and stroke are associated with MCI. A study focused on multimorbidity and MCI showed that patients with&#x000a0;4 or more comorbid conditions, especially&#x000a0;2 of the following: hypertension, coronary artery disease, hyperlipidemia, and osteoarthritis, have an increased risk of MCI.<xref ref-type="bibr" rid="article-144392.r6">[6]</xref><xref ref-type="bibr" rid="article-144392.r8">[8]</xref>&#x000a0;Other chronic diseases, such as chronic obstructive pulmonary disease and diabetes mellitus, are also risk factors for MCI.<xref ref-type="bibr" rid="article-144392.r6">[6]</xref></p>
        <p>
<bold>Polypharmacy</bold>
</p>
        <p>Numerous classes and combinations of medications can have adverse impacts on memory. These include both prescription and over-the-counter medications. Some of the common classes are opiates, anxiolytics such as benzodiazepines, non-benzodiazepine sedatives/hypnotics such as zolpidem, muscle relaxants, antiepileptic, and anticholinergic medications.<xref ref-type="bibr" rid="article-144392.r9">[9]</xref>&#x000a0;Anticholinergic medications include antihistamines, antidepressants, urinary incontinence medications, and antipsychotics.<xref ref-type="bibr" rid="article-144392.r6">[6]</xref><xref ref-type="bibr" rid="article-144392.r10">[10]</xref>&#x000a0;Antihypertensive medications can affect cognition by causing orthostatic hypotension. Hypoglycemia due to side effects from antidiabetic agents or hyperglycemia from inadequate treatment of diabetes can cause cognitive deficits.<xref ref-type="bibr" rid="article-144392.r6">[6]</xref>&#x000a0;Drug-to-drug interactions between medication classes can also cause cognitive loss. Medication side effects are reversible and can be improved if recognized promptly.&#x000a0;</p>
        <p>
<bold>Psychiatric Risk Factors</bold>
</p>
        <p>Depression can cause both cognitive and physical impairment and&#x000a0;can present as MCI. The cognitive deficits can be reversed with adequate treatment of depression. Depression can also accelerate the progression of MCI to dementia.<xref ref-type="bibr" rid="article-144392.r6">[6]</xref>&#x000a0;Late-life anxiety has also been reported to be a risk factor for cognitive decline.<xref ref-type="bibr" rid="article-144392.r11">[11]</xref></p>
        <p><bold>Metabolic or Infectious Causes</bold>&#x000a0;</p>
        <p>Hypothyroidism, vitamin B12 deficiency, dehydration, hypo or hyperglycemia, and infections such as urinary tract infections can all cause cognitive impairment and are easily treated.<xref ref-type="bibr" rid="article-144392.r6">[6]</xref></p>
        <p><bold>Sleep Disorders</bold>&#x000a0;</p>
        <p>Obstructive Sleep Apnea causes daytime fatigue and, if untreated, can cause cognitive dysfunction. The affected cognitive domains include executive function, attention, verbal or visual memory, visuospatial ability, and information processing. Continuous Positive Airway Pressure (CPAP) treatment may improve cognitive symptoms.<xref ref-type="bibr" rid="article-144392.r12">[12]</xref></p>
        <p>
<bold>Neurological Disorder</bold>
</p>
        <p>Normal Pressure Hydrocephalus is caused by cerebrospinal fluid (CSF) accumulation in the brain's ventricular system, causing ventricular enlargement. It presents as a triad of ataxic gait, urinary incontinence, and cognitive impairment. The cognitive changes are reversible if there is early diagnosis and treatment.<xref ref-type="bibr" rid="article-144392.r6">[6]</xref></p>
        <p>MCI may also represent a prodromal stage of dementia. For some conditions, the disease manifests first with cognitive impairment in the later stage of the disease course. These conditions include Parkinson Disease (PD), traumatic brain injury (TBI), Huntington disease, Human Immunodeficiency Virus (HIV) infection, and cerebrovascular accident. The Movement Disorder Society (MDS) PD-MCI criteria require that impaired cognitive domains be specified to see whether different cognitive impairments progress at different rates.<xref ref-type="bibr" rid="article-144392.r13">[13]</xref>&#x000a0;There are other diseases where cognitive impairment is the first manifestation of the disease process, such as Alzheimer Disease, Lewy body disease, prion disease, frontotemporal dementia, and vascular dementia. MCI can be the prodromal stage; in these cases, it will progress to dementia. Amnestic MCI may progress to AD or vascular dementia, while non-amnestic MCI commonly develops into Lewy body disease or frontotemporal dementia.<xref ref-type="bibr" rid="article-144392.r6">[6]</xref></p>
        <p>Some protective factors are associated with a reduced incidence of dementia or delayed dementia onset. These factors may also be protective for MCI. Higher education, bilingualism, and cognitively stimulating activities protect cognition. Lifestyle factors such as the Mediterranean diet, physical activity, smoking cessation, mild to moderate alcohol consumption, and participation in social activities are associated with reduced risk of cognitive impairment.<xref ref-type="bibr" rid="article-144392.r11">[11]</xref><xref ref-type="bibr" rid="article-144392.r3">[3]</xref></p>
      </sec>
      <sec id="article-144392.s3" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>MCI is a heterogeneous syndrome as there is a wide variation of cognitive and functional severity within the MCI definition. There are no standardized criteria for the diagnosis of MCI that have high clinical reliability and validity and provide consistent estimates across various studies. Hence, multiple studies have reported varying incidence and prevalence estimates.<xref ref-type="bibr" rid="article-144392.r14">[14]</xref>&#x000a0;The 2018 American Academy of Neurology (AAN) guideline update on MCI found that its prevalence is high among the older adult population and increases with age. The prevalence estimate was 6.7% in the 60-64 year age group and increased to 25.2% for ages 80-84.<xref ref-type="bibr" rid="article-144392.r15">[15]</xref>&#x000a0;Other studies have reported prevalence rates of up to 22% in community-dwelling older adults above 71 years of age and 40% among older adults in memory care practices.<xref ref-type="bibr" rid="article-144392.r8">[8]</xref>&#x000a0;Lower educational level was associated with a higher prevalence, while most studies found a similar prevalence in men and women.<xref ref-type="bibr" rid="article-144392.r15">[15]</xref>&#x000a0;Other studies have reported a higher prevalence in men.<xref ref-type="bibr" rid="article-144392.r9">[9]</xref>&#x000a0;The differences in the reported prevalence of MCI worldwide are due to the lack of standardized cut-off for neuropsychology test scores, use of population versus clinic-based cohorts, and algorithmic (non-informant-based) versus clinical approaches to assign the MCI diagnosis.<xref ref-type="bibr" rid="article-144392.r14">[14]</xref>&#x000a0;European studies reported a lower prevalence estimate than those reported by the US studies. Prevalence estimates were higher for those US studies conducted in urban settings and those that included ethnic groups other than Caucasians.<xref ref-type="bibr" rid="article-144392.r14">[14]</xref>&#x000a0;A recent study from China estimated that MCI prevalence was 15.5 % among Chinese adults.<xref ref-type="bibr" rid="article-144392.r16">[16]</xref>&#x000a0;There are fewer studies on the incidence rate of MCI. The reported incidence rate of MCI varies from 5.1 to 168 (1000 person-years), while that of A-MCI is estimated between 10 to 14 (1000 person-years).<xref ref-type="bibr" rid="article-144392.r14">[14]</xref></p>
      </sec>
      <sec id="article-144392.s4" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>MCI can have several outcomes, with the most important being the progression to dementia. Other cases&#x000a0;may revert to normal or remain stable in the MCI stage.</p>
        <p>A meta-analysis demonstrated that the cumulative incidence of dementia development was 14.9% for MCI patients older than 65 years who were followed for 2 years. The relative risk for all types of dementia was 3.3 at 2 to 5 years in a cohort of MCI patients and age-matched controls, while the relative risk for the development of Alzheimer Disease was 3.0. People with MCI are at a higher risk of progressing to dementia than age-matched controls.<xref ref-type="bibr" rid="article-144392.r15">[15]</xref>&#x000a0;The annual progression rate can be 12% in the general population and up to 20% in high-risk populations.<xref ref-type="bibr" rid="article-144392.r8">[8]</xref>&#x000a0;The risk factors for the development of MCI are not consistently associated with progression to dementia. Markers of cerebral dysfunction and those indicating the severity of underlying pathology are more consistently related to the risk of progressing to dementia.<xref ref-type="bibr" rid="article-144392.r14">[14]</xref>&#x000a0;More significant functional impairment, neuropsychiatric symptoms at the time of MCI diagnosis, lower neuropsychological test scores, and abnormalities on structural magnetic resonance imaging (hippocampal atrophy) are associated with a greater risk of conversion to dementia.<xref ref-type="bibr" rid="article-144392.r14">[14]</xref>&#x000a0;Some studies have noted that advanced age and amnestic MCI were associated with faster progression to dementia.<xref ref-type="bibr" rid="article-144392.r8">[8]</xref>&#x000a0;A stepwise multivariate regression analysis study reported that parietal glucose metabolic rate and total Tau proteins could predict progression from MCI to Alzheimer-type dementia.<xref ref-type="bibr" rid="article-144392.r17">[17]</xref>&#x000a0;The presence of APOE &#x003b5;4 allele is also associated with a higher risk of Alzheimer-type dementia in MCI patients.<xref ref-type="bibr" rid="article-144392.r8">[8]</xref></p>
        <p>Studies have shown that the reversion rate to normal can vary from 14.4% to 55.6%.<xref ref-type="bibr" rid="article-144392.r15">[15]</xref>&#x000a0;An average of 20% of individuals with MCI may revert to normal cognition; however, they remain at higher risk of progression back to MCI or dementia than those who were never diagnosed with MCI.<xref ref-type="bibr" rid="article-144392.r14">[14]</xref><xref ref-type="bibr" rid="article-144392.r15">[15]</xref>&#x000a0;Factors associated with reversion to normal include male sex, younger age, single domain MCI, non-amnestic MCI, better scores on objective cognitive instruments (higher Mini-Mental State Examination score or lower CDR sum of boxes score), less functional deficits, lower burden of medical disease, and presence of reversible factors (such as infection).<xref ref-type="bibr" rid="article-144392.r14">[14]</xref></p>
        <p>MCI does not have a linear trajectory for progression toward dementia or reversion to normal. Patients with stable MCI can change subtypes,&#x000a0;revert&#x000a0;to normal, convert to MCI, or progress to dementia.<xref ref-type="bibr" rid="article-144392.r18">[18]</xref><xref ref-type="bibr" rid="article-144392.r19">[19]</xref></p>
      </sec>
      <sec id="article-144392.s5" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>The neuropathology of MCI also displays considerable heterogeneity.</p>
        <p><bold>Gross Morphology</bold>&#x000a0;</p>
        <p>It&#x000a0;is difficult to distinguish between no cognitive impairment and mild cognitive impairment on autopsy. One study observed a widening of sulci in amnestic MCI and mild AD as compared to no cognitive impairment (NCI) or non-amnestic MCI.<xref ref-type="bibr" rid="article-144392.r20">[20]</xref></p>
        <p>
<bold>Amyloid Pathology&#x000a0;</bold>
</p>
        <p>Amyloid beta (A&#x003b2;) plaques are a characteristic lesion seen in MCI. These plaques appear similar in patients with normal cognition and those with MCI and cannot be used to distinguish between these two states.<xref ref-type="bibr" rid="article-144392.r20">[20]</xref>&#x000a0;Plaque density increased with progressing dementia, and the morphology changed from diffuse to neuritic.<xref ref-type="bibr" rid="article-144392.r20">[20]</xref>&#x000a0;The Rush Religious Orders Study (RROS) found that although the A&#x003b2;-amyloid burden in MCI was intermediate between normal controls and early AD, the difference was not statistically significant, suggesting that&#x000a0;&#x003b2; amyloid deposition does not define the pathological transition to MCI.<xref ref-type="bibr" rid="article-144392.r21">[21]</xref></p>
        <p>
<bold>Neurofibrillary Tangle (NFT) Pathology&#x000a0;</bold>
</p>
        <p>NFTs are composed of hyperphosphorylated aggregates of the tau protein. NFT deposition is increased in certain anatomical brain regions (such as the Entorhinal cortex and Inferior Parietal Cortex) in MCI patients compared to normal controls, suggesting that NFTs could mark the transition from normal aging to MCI.<xref ref-type="bibr" rid="article-144392.r20">[20]</xref>&#x000a0;Studies have also shown that NFTs are present in both amnestic and non-amnestic MCI subtypes, whereas about 52% of MCI cases did not have neuritic plaques.<xref ref-type="bibr" rid="article-144392.r22">[22]</xref>&#x000a0;Studies have shown that amnestic MCI is similar to early AD based on NFT distribution.<xref ref-type="bibr" rid="article-144392.r23">[23]</xref><xref ref-type="bibr" rid="article-144392.r24">[24]</xref></p>
        <p>
<bold>Neuronal Loss&#x000a0;&#x000a0;</bold>
</p>
        <p>Various studies have examined the neuronal changes in MCI, focusing on the medial temporal lobe (MTL), particularly the Entorhinal Cortex (ERC). The RROS study showed&#x000a0;neuronal reduction in the ERC and ERC atrophy in MCI patients.<xref ref-type="bibr" rid="article-144392.r20">[20]</xref>&#x000a0;ERC atrophy was also correlated with impairments in the MMSE, indicating that ERC neurodegeneration influences the progression of MCI.<xref ref-type="bibr" rid="article-144392.r25">[25]</xref><xref ref-type="bibr" rid="article-144392.r26">[26]</xref></p>
        <p>
<bold>Synaptic Degeneration in the Hippocampus</bold>
</p>
        <p>The hippocampus shows reduced synaptic plasticity in MCI.<xref ref-type="bibr" rid="article-144392.r20">[20]</xref>&#x000a0;The number of synapses is reduced in MCI when compared to controls with NCI, and people with early AD have&#x000a0;a significantly lower number of synapses when compared with MCI and NCI groups. The number of synapses also correlated with MMSE and delayed recall scores.<xref ref-type="bibr" rid="article-144392.r27">[27]</xref></p>
        <p>
<bold>Cholinergic System and Acetylcholine Receptors</bold>
</p>
        <p>Reduction in the cholinergic activity in the cortex and loss of neurons in the cholinergic basal forebrain (CBF) has been proposed as a potential mechanism for AD. In MCI, deposition of NFTs was noted in the CBF; however, the number of CBF nucleus basalis (NB) neurons that express choline acetyltransferase enzyme (ChAT) or the acetylcholine transporter was stable.<xref ref-type="bibr" rid="article-144392.r20">[20]</xref>&#x000a0;Cholinergic receptor binding in ERC is lower in MCI than in NCI, while it is lower in the hippocampus in AD than in MCI, leading to cognitive deficits. This indicates that cholinergic system dysfunction could be responsible for cognitive changes seen in MCI.<xref ref-type="bibr" rid="article-144392.r28">[28]</xref></p>
        <p><bold>Other Neuropathologies</bold>&#x000a0;</p>
        <p>Lewy Bodies (LB), cerebral white matter rarefaction (CWMR), infarcts, and cerebral amyloid angiopathy (CAA) are some of the other findings observed in neuropathology studies. Non-amnestic MCI shows a greater distribution of LBs in the temporal lobes than amnestic MCI.<xref ref-type="bibr" rid="article-144392.r22">[22]</xref>&#x000a0;CWMR and CAA are equally common in both amnestic and non-amnestic MCI; however, cases with executive dysfunction had a higher frequency of CWMR and CAA.<xref ref-type="bibr" rid="article-144392.r22">[22]</xref>&#x000a0;Multiple studies have shown that mixed pathologies are a common feature of MCI.</p>
      </sec>
      <sec id="article-144392.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Cognitive disorders are diagnosed clinically. Obtaining a comprehensive history from the patient or a reliable informant is important. Sometimes, the patients or their family members or caregivers are concerned about memory loss and may request an evaluation. At other times, neither the patient nor their families report concerns unless the physician asks them directly. Patients with memory loss may have poor insight into their impairment. Hence, it is necessary to obtain collateral information from someone who knows the patient well to obtain an accurate history. Sometimes, the patient's physician or a clinical staff member may be the first to recognize cognitive challenges when a patient misses their appointments, forgets to refill their medications, or&#x000a0;gets confused by&#x000a0;simple instructions. Periodically, the initial complaint may be a mood or behavioral problem rather than a cognitive one. Anxiety, depression, apathy, and other personality changes may prompt a request for the assessment.&#x000a0;</p>
        <p>Information about the onset and progression of symptoms should be noted. Usually, the symptoms are gradual in onset and progressive. Sometimes, the patients or their families may attribute these to normal aging. The AAN recommends that all memory concerns be assessed for MCI and not assumed to be due to normal aging.<xref ref-type="bibr" rid="article-144392.r15">[15]</xref></p>
        <p>The purpose of the evaluation is to distinguish MCI from normal aging or dementia and to ascertain if any reversible factors may be responsible for the presentation. When determining a patient's baseline function, it is important to gather and consider information about their educational level and occupation.&#x000a0;</p>
        <p>A detailed assessment can identify affected cognitive domains. The complaint should represent a change from the baseline for the patient. The table below shows some examples.<xref ref-type="bibr" rid="article-144392.r11">[11]</xref></p>
        <table-wrap id="article-144392.table1" position="float" orientation="portrait">
          <table style="width: 800px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr style="height: 22px;">
                <td style="width: 141px; height: 22px;" rowspan="1" colspan="1">
<bold>&#x000a0;Cognitive Domain&#x000a0;</bold>
</td>
                <td style="width: 754.078px; height: 22px;" rowspan="1" colspan="1"><bold>&#x000a0;Examples in Daily Life</bold>&#x000a0;</td>
              </tr>
              <tr style="height: 34px;">
                <td style="width: 141px; height: 34px;" rowspan="1" colspan="1">&#x000a0;Complex attention&#x000a0;</td>
                <td style="width: 754.078px; height: 34px;" rowspan="1" colspan="1">&#x000a0;Easily distracted, tasks take longer than normal, tasks need to be simplified, difficulty with mental calculations&#x000a0;</td>
              </tr>
              <tr style="height: 25px;">
                <td style="width: 141px; height: 25px;" rowspan="1" colspan="1">&#x000a0;Executive functioning&#x000a0;</td>
                <td style="width: 754.078px; height: 25px;" rowspan="1" colspan="1">&#x000a0;Difficulty with multi-tasking, planning, and organization, following conversations&#x000a0;</td>
              </tr>
              <tr style="height: 30px;">
                <td style="width: 141px; height: 30px;" rowspan="1" colspan="1">&#x000a0;Learning and memory</td>
                <td style="width: 754.078px; height: 30px;" rowspan="1" colspan="1">&#x000a0;Misplacing items, repeating questions and conversations, forgetting recent events, relying more on lists</td>
              </tr>
              <tr style="height: 34px;">
                <td style="width: 141px; height: 34px;" rowspan="1" colspan="1">&#x000a0;Language&#x000a0;</td>
                <td style="width: 754.078px; height: 34px;" rowspan="1" colspan="1">&#x000a0;Word-finding problems, using the wrong words, grammatical mistakes, difficulty understanding others' speech or written material</td>
              </tr>
              <tr style="height: 21px;">
                <td style="width: 141px; height: 21px;" rowspan="1" colspan="1">&#x000a0;Visuospatial function</td>
                <td style="width: 754.078px; height: 21px;" rowspan="1" colspan="1">&#x000a0;Difficulty using familiar appliances, getting turned out in familiar places (outside or inside their house)</td>
              </tr>
              <tr style="height: 33px;">
                <td style="width: 141px; height: 33px;" rowspan="1" colspan="1">&#x000a0;Social cognition&#x000a0;</td>
                <td style="width: 754.078px; height: 33px;" rowspan="1" colspan="1">&#x000a0;Apathy or disinhibition, lack of empathy, socially inappropriate behavior&#x000a0;</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>The cognitive history should be followed by a detailed functional history inquiring about instrumental activities of daily living (IADLs) and basic activities of daily living (BADLs). Changes in complex functions such as difficulty managing finances, medications, or driving should be asked about. In MCI, the patients&#x000a0;may report functional independence&#x000a0;alongside their&#x000a0;cognitive complaints. It can sometimes be challenging to determine if the IADLs are impaired. Patients with higher educational levels or those in cognitively challenging occupations (such as physicians) may report mild changes that affect their professional performance. In contrast, those with lifelong lower-skill jobs may not report any problems.<xref ref-type="bibr" rid="article-144392.r29">[29]</xref>&#x000a0;Assessing functional impairment related to cognition is vital to distinguish MCI from dementia.<xref ref-type="bibr" rid="article-144392.r15">[15]</xref></p>
        <p>A detailed medication review involving prescription and over-the-counter medications is integral to the evaluation.&#x000a0;The Beers Criteria for Potentially Inappropriate Medication (PIM) Use in Older Adults, developed by the American Geriatrics Society, is useful for identifying medications that can contribute to cognitive impairment.<xref ref-type="bibr" rid="article-144392.r10">[10]</xref></p>
        <p>Neuropsychiatric symptoms&#x000a0;are quite common in MCI, with 35-85% of patients showing at least one neuropsychiatric symptom.<xref ref-type="bibr" rid="article-144392.r30">[30]</xref>&#x000a0;Depression, apathy, anxiety, irritability, sleep problems (difficulty falling asleep, early morning waking, wandering at night), agitation, appetite or eating disorder, and disinhibition can be seen commonly in MCI. Hallucinations and delusions are unusual in MCI patients but associated with worse outcomes if present.<xref ref-type="bibr" rid="article-144392.r31">[31]</xref>&#x000a0;It can sometimes be difficult to evaluate if depression and anxiety are a cause of MCI or associated. Screening for sleep-disordered breathing such as OSA, asking questions about vision, hearing, gait, history of falls, recent hospitalizations, tingling/numbness, urinary incontinence, tremors, and speech problems are included in the history.&#x000a0;</p>
        <p>A complete neurological examination should be performed. This should include assessments for cranial nerves, focal weakness, coordination, ability to stand from a chair without using hand rests, gait, and speech evaluation to look for dysarthria and orthostatic hypotension to identify potential contributors to the cognitive complaint.<xref ref-type="bibr" rid="article-144392.r9">[9]</xref></p>
        <p>The history and physical exam help identify conditions such as stroke, NPH, PD, or neuropathy due to vitamin deficiency as a cause of the symptoms.&#x000a0;</p>
      </sec>
      <sec id="article-144392.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>A standardized cognitive assessment is mandatory to establish a diagnosis of MCI. Standard screening tools that&#x000a0;are used include the Montreal Cognitive Assessment (MOCA), the Saint Louis University Mental Status Examination (SLUMS), and the Mini-Mental State Exam (MMSE). A history of subjective memory concerns is insufficient to diagnose MCI, and further assessment with a validated tool is required per the AAN practice guidelines.<xref ref-type="bibr" rid="article-144392.r15">[15]</xref></p>
        <p>The MOCA&#x000a0;is a 30-point questionnaire specifically designed to detect MCI, takes about 10 minutes to administer, tests multiple cognitive domains, and is validated in multiple languages. The MOCA also accounts for educational level, granting an additional point for patients with less than 12 years of education.<xref ref-type="bibr" rid="article-144392.r32">[32]</xref>&#x000a0;Using a cut-off score of 25- 26, MOCA had a sensitivity of 80-100% and specificity of 50-76% for detecting MCI.<xref ref-type="bibr" rid="article-144392.r9">[9]</xref>&#x000a0;The MMSE is also a 30-point questionnaire but is less sensitive than the MOCA for detecting MCI, with a sensitivity of 45-60% when using a cut-off score of 27-28.<xref ref-type="bibr" rid="article-144392.r9">[9]</xref>&#x000a0;MOCA's assessment tasks are more varied and challenging and can better distinguish patients with mild changes in executive function, complex visuospatial function, and language abilities than the MMSE.<xref ref-type="bibr" rid="article-144392.r33">[33]</xref>&#x000a0;</p>
        <p>Correcting the MMSE score for education can create a ceiling effect for people with low education levels and a floor effect for those with higher educational levels.<xref ref-type="bibr" rid="article-144392.r34">[34]</xref>&#x000a0;This means that the MMSE can overestimate the extent of cognitive dysfunction in poorly educated populations and underestimate the highly educated ones. Another limitation of MMSE is that its use is copyrighted. The SLUMS is a 30-point questionnaire with an administration time of 10 minutes. It is more sensitive to detect defects in executive function, commonly impaired in MCI, hence a better screening tool for MCI than the MMSE. The SLUMS has cut-off scores for MCI based on the educational level (unlike the MMSE), is better validated for detecting MCI, and is free to use.<xref ref-type="bibr" rid="article-144392.r35">[35]</xref>&#x000a0;</p>
        <p>The DSM-V or the NIA-AA MCI criteria do not specify the use of a particular screening test; however, the scores need to be 1 to 2 standard deviations below the education and age-adjusted normative means. The scores are used as guidelines and not firm cut-offs for diagnosing MCI.<xref ref-type="bibr" rid="article-144392.r5">[5]</xref>&#x000a0;Referral for neuropsychology testing can be considered to specify the type and extent of cognitive deficits, and it&#x000a0;is instrumental in cases where the deficits are subtle.</p>
        <p>Clinicians can also collect information on cognitive function from informants using standardized tools such as the Informant Questionnaire on Cognitive Decline in the Elderly(IQCODE), the Dementia Severity Rating Scale (DSRS), and the AD8.<xref ref-type="bibr" rid="article-144392.r9">[9]</xref>&#x000a0;Geriatric Depression Scale can be used to screen for depression, with a score of&#x000a0;&#x02265;6 suggesting depression.<xref ref-type="bibr" rid="article-144392.r36">[36]</xref></p>
        <p>After establishing the diagnosis of MCI based on clinical examination and cognitive testing, diagnostic tests are ordered to determine the etiology of the deficits and identify treatable causes.&#x000a0;</p>
        <p>Routine laboratory testing includes tests for complete blood counts, thyroid function, vitamin B12, folate, and metabolic panel to check electrolytes, glucose, and renal function to identify reversible causes of MCI. Tests for liver function, syphilis, HIV, hepatitis (B or C), and Lyme disease may be ordered based on clinical suspicion.&#x000a0;</p>
        <p>The clinical utility of biomarker studies is limited due to a lack of standardized techniques and cut-off scores for diagnosis. The most common biomarkers&#x000a0;detect pathological changes in AD characterized by low cerebrospinal fluid levels of A&#x003b2; 42 and elevated levels of the tau protein.<xref ref-type="bibr" rid="article-144392.r6">[6]</xref>&#x000a0;These may help identify MCI patients at high risk of progressing to AD, but biomarkers are not recommended as part of the evaluation.<xref ref-type="bibr" rid="article-144392.r9">[9]</xref><xref ref-type="bibr" rid="article-144392.r15">[15]</xref></p>
        <p>Structural neuroimaging studies include magnetic resonance imaging (MRI) or computerized tomography (CT) brain scans. These can help rule out conditions such as stroke, brain tumors, NPH, or subdural hematoma as a cause of cognitive dysfunction. They can also show small vessel ischemic changes or white matter hyperintensities, which&#x000a0;usually indicate cognitive impairment due to vascular dementia.<xref ref-type="bibr" rid="article-144392.r6">[6]</xref>&#x000a0;Volumetric MRI can show hippocampal atrophy correlated with progression to dementia. This imaging modality is&#x000a0;selectively available at institutions, limiting its clinical use.<xref ref-type="bibr" rid="article-144392.r6">[6]</xref>&#x000a0;</p>
        <p>Functional neuroimaging studies such as positron emission tomography (PET) scans with F-fluorodeoxyglucose (FDG) or single photon emission computed tomography (SPECT) evaluate brain function. FDG-PET measures areas of glucose hypometabolism in the brain, indicating neurodegeneration, while SPECT measures cerebral blood flow.<xref ref-type="bibr" rid="article-144392.r6">[6]</xref>&#x000a0;These studies are limited to research settings.</p>
        <p>Genetic testing for the APOE genotype is not recommended as a diagnostic test.<xref ref-type="bibr" rid="article-144392.r37">[37]</xref></p>
        <p>MCI is a clinical diagnosis, as there are no&#x000a0;definitive&#x000a0;screening tests. Periodic clinical assessments are needed to monitor the trajectory of the condition.<xref ref-type="bibr" rid="article-144392.r15">[15]</xref>&#x000a0;The AAN guidelines also recommend referral to a cognitive specialist if the clinicians do not have experience treating patients with cognitive impairment.<xref ref-type="bibr" rid="article-144392.r15">[15]</xref></p>
      </sec>
      <sec id="article-144392.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treatment of reversible causes should be prioritized; conditions such as OSA, depression, hypothyroidism, vitamin deficiency, and polypharmacy are&#x000a0;easily treated and may lead to the reversal of cognitive impairment. Vascular risk factors such as hyperlipidemia, hypertension, diabetes mellitus, atrial fibrillation, and tobacco and alcohol use&#x000a0;should be addressed to slow down ischemic damage.&#x000a0;</p>
        <p>Currently, there are no FDA-approved agents for the treatment of MCI. Several pharmacological agents have been studied for efficacy in treating MCI. These include acetylcholine esterase inhibitors donepezil, galantamine, and rivastigmine, homocysteine-lowering B vitamins, flavonoid-containing drinks, vitamin E, vitamin C, transdermal nicotine patch, piribedil, rofecoxib, tesamorelin injections, and V0191. Donepezil and other medications used for AD are not effective in reducing the progression of MCI.<xref ref-type="bibr" rid="article-144392.r1">[1]</xref>&#x000a0;</p>
        <p>The 2018 AAN practice guidelines advise against pharmacologic or dietary agents for MCI treatment.<xref ref-type="bibr" rid="article-144392.r15">[15]</xref>&#x000a0;The guidelines recommend that clinicians discuss with the patient before choosing not to offer cholinesterase inhibitors or prescribing them off-label. Patients should also be provided information about&#x000a0;relevant clinical trials if they are interested in pharmacologic treatment.<xref ref-type="bibr" rid="article-144392.r15">[15]</xref></p>
        <p>Non-pharmacologic interventions such as exercise and cognitive training have also been studied for MCI treatment. A six-month randomized controlled trial resistance training exercise twice weekly showed improved cognitive function compared to weekly balance and tone exercises.<xref ref-type="bibr" rid="article-144392.r2">[2]</xref>&#x000a0;Another study showed that multicomponent exercise could improve cognitive function in MCI. A systematic review and meta-analysis have shown the usefulness of cognitive interventions on metacognition and activities of daily living.<xref ref-type="bibr" rid="article-144392.r1">[1]</xref>&#x000a0;Cognitively stimulating activities, such as crossword puzzles, card games, and frequent socialization, can help prevent the progression of MCI.<xref ref-type="bibr" rid="article-144392.r6">[6]</xref>&#x000a0;The AAN guidelines recommend regular exercise (twice per week) and cognitive interventions as part of management for general health benefits and low risk.<xref ref-type="bibr" rid="article-144392.r15">[15]</xref></p>
        <p>The inherent uncertainty about the progression of MCI and the lack of effective pharmacologic agents necessitates that physicians educate patients about the&#x000a0;progression to dementia and engage in planning for the future. Patients should be encouraged to designate medical and financial power of attorneys and complete advance directives or living wills if they cannot make such decisions in the future. Potentially hazardous circumstances such as driving, gun safety, and vulnerability to financial scams can be discussed.<xref ref-type="bibr" rid="article-144392.r6">[6]</xref><xref ref-type="bibr" rid="article-144392.r15">[15]</xref>&#x000a0;In addition to discussing long-term planning, the AAN recommends assessing and treating neuropsychiatric symptoms when indicated.<xref ref-type="bibr" rid="article-144392.r15">[15]</xref></p>
        <p>Optimizing visual and auditory function is important, as untreated problems can lead to cognitive decline.<xref ref-type="bibr" rid="article-144392.r38">[38]</xref>&#x000a0;Targeted interventions to improve gait and balance to reduce the risk of falls should be recommended.<xref ref-type="bibr" rid="article-144392.r9">[9]</xref>&#x000a0;Caregivers can experience distress and have conflicting feelings towards the patient in response to the cognitive and behavioral changes seen in MCI. It is important to provide support and services to the caregivers depending on their needs.<xref ref-type="bibr" rid="article-144392.r7">[7]</xref></p>
      </sec>
      <sec id="article-144392.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>It is important to differentiate MCI from both normal aging&#x000a0;and dementia. Subjective reports from the patient or a reliable caregiver, a history of functional decline, and objective assessment with a standardized cognitive screening tool help to distinguish these conditions. Reversible causes of MCI, such as depression and OSA, need to be ruled out. MCI can represent the prodromal stage of different types of dementia, and the subtype of MCI can&#x000a0;provide important clues about the etiology.&#x000a0;</p>
        <p>AD can present&#x000a0;from all&#x000a0;4 MCI subtypes - single or multiple domain A-MCI, single or multiple domain NA-MCI. Depression can present as amnestic MCI. FTD can present as a single domain NA-MCI. Vascular cognitive impairment can present as multiple-domain amnestic or non-amnestic MCI. Lewy body dementia can present as multiple-domain NA-MCI.<xref ref-type="bibr" rid="article-144392.r2">[2]</xref>&#x000a0;In Parkinson Disease, a single-domain NA-MCI is usually seen.<xref ref-type="bibr" rid="article-144392.r1">[1]</xref></p>
      </sec>
      <sec id="article-144392.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis of MCI is uncertain. There is great variability in progression rates of MCI to dementia, with studies reporting annual conversion rates from &#x0003c;5%-12-20%.<xref ref-type="bibr" rid="article-144392.r9">[9]</xref>&#x000a0;40-70% of patients with MCI may not progress to dementia for over a decade.<xref ref-type="bibr" rid="article-144392.r39">[39]</xref>&#x000a0;About 15-20% of MCI patients will report improved cognition in 1 to 2 years, although this group remains at a higher risk of future cognitive decline.<xref ref-type="bibr" rid="article-144392.r40">[40]</xref></p>
        <p>Risk factors associated with MCI progression include amnestic MCI subtype, older age, stroke, diabetes, and lower educational level.<xref ref-type="bibr" rid="article-144392.r8">[8]</xref>&#x000a0;APOE genotype may confer a modest risk of progression to AD.<xref ref-type="bibr" rid="article-144392.r41">[41]</xref>&#x000a0;Factors associated with reversion to normal cognition include non-amnestic MCI subtype, younger age, higher baseline cognitive function, and higher educational level.<xref ref-type="bibr" rid="article-144392.r40">[40]</xref>&#x000a0;MCI subtype classification can be used to estimate progression risk; however, this model has variable predictive accuracy. Current risk prediction models are limited in presaging the risk of progression to dementia.<xref ref-type="bibr" rid="article-144392.r9">[9]</xref>&#x000a0;Future risk prediction models need to account for competing risks, such as cardiovascular disease and cancer, that can cause mortality before the patient develops dementia.<xref ref-type="bibr" rid="article-144392.r9">[9]</xref></p>
      </sec>
      <sec id="article-144392.s11" sec-type="Complications">
        <title>Complications</title>
        <p>The most important complication of MCI is progression to dementia. Early diagnosis and treatment of MCI are important because they help patients plan for the future so that&#x000a0;emergencies or late-stage complications&#x000a0;are avoided. Assessment and treatment of reversible causes can help stabilize or reverse the cognitive changes.<xref ref-type="bibr" rid="article-144392.r6">[6]</xref></p>
      </sec>
      <sec id="article-144392.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Currently, there are no treatments that can reduce the risk of MCI. However, control of vascular risk factors may be important. The treatment of hypertension might reduce the risk of developing MCI and the composite result of MCI and probable dementia.<xref ref-type="bibr" rid="article-144392.r42">[42]</xref>&#x000a0;Treating other vascular risk factors, such as diabetes mellitus, hyperlipidemia, and obesity, should follow the cardiovascular and cerebrovascular prevention guidelines.<xref ref-type="bibr" rid="article-144392.r43">[43]</xref>&#x000a0;Concurrent treatment is required for conditions such as OSA, depression, hypothyroidism, polypharmacy, and hearing impairment.<xref ref-type="bibr" rid="article-144392.r43">[43]</xref>&#x000a0;</p>
        <p>Educating patients and families about the natural course of MCI and the risk factors for progression is important. Clinicians should admit the challenges in predicting individual risk of progression to dementia and emphasize the need for continued monitoring.<xref ref-type="bibr" rid="article-144392.r9">[9]</xref>&#x000a0;Patient engagement in advance care planning and outlining goals of care is encouraged depending on the stage of MCI. Providing education regarding the difference between MCI, dementia, and Alzheimer disease&#x000a0;is helpful to mitigate stress.<xref ref-type="bibr" rid="article-144392.r43">[43]</xref>&#x000a0;Patients can be guided to the websites of the&#x000a0; Alzheimer's Association (alz.org) and the National Institute on Aging (nia.nih.gov) for more information and resources.<xref ref-type="bibr" rid="article-144392.r43">[43]</xref>&#x000a0;Lifestyle interventions should encourage physical activity, a healthy diet, and social or cognitive stimulation.<xref ref-type="bibr" rid="article-144392.r9">[9]</xref>&#x000a0;Caregivers of patients with MCI should be encouraged to take care of their own physical and mental well-being to&#x000a0;reduce caregiver stress.<xref ref-type="bibr" rid="article-144392.r43">[43]</xref></p>
      </sec>
      <sec id="article-144392.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>MCI is a heterogenous syndrome with uncertain outcomes. Patients with MCI are at an increased risk of progressing to dementia so early screening and diagnosis are important. MCI can also have reversible causes; collaboration with interprofessional teams is important to improve patient outcomes. Management of memory changes is comprehensive and requires collaboration among various healthcare professionals, community agencies, and the patient and their families. Primary care physicians can refer patients with cognitive complaints to specialists such as geriatricians, neurologists, or psychiatrists if they do not feel confident evaluating such patients or have time constraints. Neuropsychologists can help conduct detailed cognitive assessments to better characterize cognitive deficits. Sleep medicine physicians and advanced practice practitioners can help evaluate and treat sleep disorders. Psychiatric or geriatric psychiatry and other behavioral health team members can manage mood disorders or other behavioral symptoms. Pharmacists can assist primary or specialty care physicians in identifying and avoiding inappropriate medications. Physical and occupational therapists can help with gait training, home safety, and driving safety. Speech-language pathologists can help patients improve communication skills. Social workers help identify community resources and provide education and emotional support to patients and their caregivers. Organizations such as the Local Area Agencies on Aging and the Alzheimer's Association offer caregiver support groups for caregiver training and education. An elder law attorney can help patients appoint medical and financial power of attorney.</p>
        <p>It is important to recognize racial, ethnic, and cultural perspectives on aging to identify how to connect with patients' support networks and develop a suitable management plan for their needs.&#x000a0;</p>
      </sec>
      <sec id="article-144392.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=144392&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=144392">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/health/mild-cognitive-impairment/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=144392">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/144392/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=144392">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-144392.s15">
        <title>References</title>
        <ref id="article-144392.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jongsiriyanyong</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Limpawattana</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Mild Cognitive Impairment in Clinical Practice: A Review Article.</article-title>
            <source>Am J Alzheimers Dis Other Demen</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>33</volume>
            <issue>8</issue>
            <fpage>500</fpage>
            <page-range>500-507</page-range>
            <pub-id pub-id-type="pmid">30068225</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144392.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Petersen</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>Mild Cognitive Impairment.</article-title>
            <source>Continuum (Minneap Minn)</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>22</volume>
            <issue>2 Dementia</issue>
            <fpage>404</fpage>
            <page-range>404-18</page-range>
            <pub-id pub-id-type="pmid">27042901</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144392.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Petersen</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Caracciolo</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Brayne</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gauthier</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jelic</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Fratiglioni</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Mild cognitive impairment: a concept in evolution.</article-title>
            <source>J Intern Med</source>
            <year>2014</year>
            <month>Mar</month>
            <volume>275</volume>
            <issue>3</issue>
            <fpage>214</fpage>
            <page-range>214-28</page-range>
            <pub-id pub-id-type="pmid">24605806</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144392.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kasper</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bancher</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Eckert</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>F&#x000f6;rstl</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fr&#x000f6;lich</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hort</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Korczyn</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Kressig</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Levin</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Palomo</surname>
                <given-names>MSM</given-names>
              </name>
            </person-group>
            <article-title>Management of mild cognitive impairment (MCI): The need for national and international guidelines.</article-title>
            <source>World J Biol Psychiatry</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>21</volume>
            <issue>8</issue>
            <fpage>579</fpage>
            <page-range>579-594</page-range>
            <pub-id pub-id-type="pmid">32019392</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144392.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Albert</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>DeKosky</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Dickson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dubois</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Fox</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Gamst</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Holtzman</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Jagust</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Petersen</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Snyder</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Carrillo</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Thies</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Phelps</surname>
                <given-names>CH</given-names>
              </name>
            </person-group>
            <article-title>The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.</article-title>
            <source>Alzheimers Dement</source>
            <year>2011</year>
            <month>May</month>
            <volume>7</volume>
            <issue>3</issue>
            <fpage>270</fpage>
            <page-range>270-9</page-range>
            <pub-id pub-id-type="pmid">21514249</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144392.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sanford</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Mild Cognitive Impairment.</article-title>
            <source>Clin Geriatr Med</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>33</volume>
            <issue>3</issue>
            <fpage>325</fpage>
            <page-range>325-337</page-range>
            <pub-id pub-id-type="pmid">28689566</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144392.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghosh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Libon</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lippa</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Mild Cognitive Impairment: A Brief Review and Suggested Clinical Algorithm.</article-title>
            <source>Am J Alzheimers Dis Other Demen</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>29</volume>
            <issue>4</issue>
            <fpage>293</fpage>
            <page-range>293-302</page-range>
            <pub-id pub-id-type="pmid">24370618</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144392.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Campbell</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Unverzagt</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>LaMantia</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Boustani</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Risk factors for the progression of mild cognitive impairment to dementia.</article-title>
            <source>Clin Geriatr Med</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>29</volume>
            <issue>4</issue>
            <fpage>873</fpage>
            <page-range>873-93</page-range>
            <pub-id pub-id-type="pmid">24094301</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144392.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Langa</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>The diagnosis and management of mild cognitive impairment: a clinical review.</article-title>
            <source>JAMA</source>
            <year>2014</year>
            <month>Dec</month>
            <day>17</day>
            <volume>312</volume>
            <issue>23</issue>
            <fpage>2551</fpage>
            <page-range>2551-61</page-range>
            <pub-id pub-id-type="pmid">25514304</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144392.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <collab>By the 2023 American Geriatrics Society Beers Criteria&#x000ae; Update Expert Panel</collab>
            <article-title>American Geriatrics Society 2023 updated AGS Beers Criteria&#x000ae; for potentially inappropriate medication use in older adults.</article-title>
            <source>J Am Geriatr Soc</source>
            <year>2023</year>
            <month>Jul</month>
            <volume>71</volume>
            <issue>7</issue>
            <fpage>2052</fpage>
            <page-range>2052-2081</page-range>
            <pub-id pub-id-type="pmid">37139824</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144392.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hugo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ganguli</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Dementia and cognitive impairment: epidemiology, diagnosis, and treatment.</article-title>
            <source>Clin Geriatr Med</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>30</volume>
            <issue>3</issue>
            <fpage>421</fpage>
            <page-range>421-42</page-range>
            <pub-id pub-id-type="pmid">25037289</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144392.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chong</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Obstructive Sleep Apnea: Cognitive Outcomes.</article-title>
            <source>Clin Geriatr Med</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>37</volume>
            <issue>3</issue>
            <fpage>457</fpage>
            <page-range>457-467</page-range>
            <pub-id pub-id-type="pmid">34210450</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144392.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goldman</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Aggarwal</surname>
                <given-names>NT</given-names>
              </name>
              <name>
                <surname>Schroeder</surname>
                <given-names>CD</given-names>
              </name>
            </person-group>
            <article-title>Mild cognitive impairment: an update in Parkinson's disease and lessons learned from Alzheimer's disease.</article-title>
            <source>Neurodegener Dis Manag</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>5</volume>
            <issue>5</issue>
            <fpage>425</fpage>
            <page-range>425-43</page-range>
            <pub-id pub-id-type="pmid">26517759</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144392.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roberts</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Knopman</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Classification and epidemiology of MCI.</article-title>
            <source>Clin Geriatr Med</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>29</volume>
            <issue>4</issue>
            <fpage>753</fpage>
            <page-range>753-72</page-range>
            <pub-id pub-id-type="pmid">24094295</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144392.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Petersen</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Lopez</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Armstrong</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Getchius</surname>
                <given-names>TSD</given-names>
              </name>
              <name>
                <surname>Ganguli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gloss</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gronseth</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Marson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pringsheim</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Day</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Sager</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stevens</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rae-Grant</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.</article-title>
            <source>Neurology</source>
            <year>2018</year>
            <month>Jan</month>
            <day>16</day>
            <volume>90</volume>
            <issue>3</issue>
            <fpage>126</fpage>
            <page-range>126-135</page-range>
            <pub-id pub-id-type="pmid">29282327</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144392.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jia</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Du</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lyu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jiao</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gong</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zuo</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yuan</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Liao</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Lv</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Qin</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Jia</surname>
                <given-names>J</given-names>
              </name>
              <collab>COAST Group</collab>
            </person-group>
            <article-title>Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study.</article-title>
            <source>Lancet Public Health</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>5</volume>
            <issue>12</issue>
            <fpage>e661</fpage>
            <page-range>e661-e671</page-range>
            <pub-id pub-id-type="pmid">33271079</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144392.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Choo</surname>
                <given-names>IH</given-names>
              </name>
              <name>
                <surname>Ni</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sch&#x000f6;ll</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wall</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Almkvist</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Nordberg</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Combination of 18F-FDG PET and cerebrospinal fluid biomarkers as a better predictor of the progression to Alzheimer's disease in mild cognitive impairment patients.</article-title>
            <source>J Alzheimers Dis</source>
            <year>2013</year>
            <volume>33</volume>
            <issue>4</issue>
            <fpage>929</fpage>
            <page-range>929-39</page-range>
            <pub-id pub-id-type="pmid">23047371</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144392.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Overton</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pihlsg&#x000e5;rd</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Elmst&#x000e5;hl</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic Stability of Mild Cognitive Impairment, and Predictors of Reversion to Normal Cognitive Functioning.</article-title>
            <source>Dement Geriatr Cogn Disord</source>
            <year>2019</year>
            <volume>48</volume>
            <issue>5-6</issue>
            <fpage>317</fpage>
            <page-range>317-329</page-range>
            <pub-id pub-id-type="pmid">32224608</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144392.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aerts</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Heffernan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kochan</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Crawford</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Draper</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Trollor</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Sachdev</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Brodaty</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Effects of MCI subtype and reversion on progression to dementia in a community sample.</article-title>
            <source>Neurology</source>
            <year>2017</year>
            <month>Jun</month>
            <day>06</day>
            <volume>88</volume>
            <issue>23</issue>
            <fpage>2225</fpage>
            <page-range>2225-2232</page-range>
            <pub-id pub-id-type="pmid">28490651</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144392.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mufson</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Binder</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Counts</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>DeKosky</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>de Toledo-Morrell</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ginsberg</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Ikonomovic</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Perez</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Scheff</surname>
                <given-names>SW</given-names>
              </name>
            </person-group>
            <article-title>Mild cognitive impairment: pathology and mechanisms.</article-title>
            <source>Acta Neuropathol</source>
            <year>2012</year>
            <month>Jan</month>
            <volume>123</volume>
            <issue>1</issue>
            <fpage>13</fpage>
            <page-range>13-30</page-range>
            <pub-id pub-id-type="pmid">22101321</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144392.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Markesbery</surname>
                <given-names>WR</given-names>
              </name>
            </person-group>
            <article-title>Neuropathologic alterations in mild cognitive impairment: a review.</article-title>
            <source>J Alzheimers Dis</source>
            <year>2010</year>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>221</fpage>
            <page-range>221-8</page-range>
            <pub-id pub-id-type="pmid">20061641</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144392.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dugger</surname>
                <given-names>BN</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Malek-Ahmadi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hentz</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Sandhu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Beach</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>Adler</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Caselli</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Serrano</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Shill</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Belden</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Driver-Dunckley</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Caviness</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Sue</surname>
                <given-names>LI</given-names>
              </name>
              <name>
                <surname>Jacobson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Powell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sabbagh</surname>
                <given-names>MN</given-names>
              </name>
            </person-group>
            <article-title>Neuropathological comparisons of amnestic and nonamnestic mild cognitive impairment.</article-title>
            <source>BMC Neurol</source>
            <year>2015</year>
            <month>Aug</month>
            <day>20</day>
            <volume>15</volume>
            <fpage>146</fpage>
            <pub-id pub-id-type="pmid">26289075</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144392.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Petersen</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Parisi</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Dickson</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Knopman</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Boeve</surname>
                <given-names>BF</given-names>
              </name>
              <name>
                <surname>Jicha</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Ivnik</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Tangalos</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Braak</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kokmen</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Neuropathologic features of amnestic mild cognitive impairment.</article-title>
            <source>Arch Neurol</source>
            <year>2006</year>
            <month>May</month>
            <volume>63</volume>
            <issue>5</issue>
            <fpage>665</fpage>
            <page-range>665-72</page-range>
            <pub-id pub-id-type="pmid">16682536</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144392.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Markesbery</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Schmitt</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Kryscio</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Wekstein</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Neuropathologic substrate of mild cognitive impairment.</article-title>
            <source>Arch Neurol</source>
            <year>2006</year>
            <month>Jan</month>
            <volume>63</volume>
            <issue>1</issue>
            <fpage>38</fpage>
            <page-range>38-46</page-range>
            <pub-id pub-id-type="pmid">16401735</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144392.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kordower</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Stebbins</surname>
                <given-names>GT</given-names>
              </name>
              <name>
                <surname>DeKosky</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Cochran</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Bennett</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mufson</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment.</article-title>
            <source>Ann Neurol</source>
            <year>2001</year>
            <month>Feb</month>
            <volume>49</volume>
            <issue>2</issue>
            <fpage>202</fpage>
            <page-range>202-13</page-range>
            <pub-id pub-id-type="pmid">11220740</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144392.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morris</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease.</article-title>
            <source>J Mol Neurosci</source>
            <year>2001</year>
            <month>Oct</month>
            <volume>17</volume>
            <issue>2</issue>
            <fpage>101</fpage>
            <page-range>101-18</page-range>
            <pub-id pub-id-type="pmid">11816784</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144392.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scheff</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Schmitt</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Mufson</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment.</article-title>
            <source>Neurobiol Aging</source>
            <year>2006</year>
            <month>Oct</month>
            <volume>27</volume>
            <issue>10</issue>
            <fpage>1372</fpage>
            <page-range>1372-84</page-range>
            <pub-id pub-id-type="pmid">16289476</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144392.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sultzer</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Yarns</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Melrose</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Cholinergic receptor binding in unimpaired older adults, mild cognitive impairment, and Alzheimer's disease dementia.</article-title>
            <source>Alzheimers Res Ther</source>
            <year>2022</year>
            <month>Feb</month>
            <day>07</day>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>25</fpage>
            <pub-id pub-id-type="pmid">35130968</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144392.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lopez</surname>
                <given-names>OL</given-names>
              </name>
            </person-group>
            <article-title>Mild cognitive impairment.</article-title>
            <source>Continuum (Minneap Minn)</source>
            <year>2013</year>
            <month>Apr</month>
            <volume>19</volume>
            <issue>2 Dementia</issue>
            <fpage>411</fpage>
            <page-range>411-24</page-range>
            <pub-id pub-id-type="pmid">23558486</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144392.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gallagher</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Iaboni</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Neuropsychiatric Symptoms in Mild Cognitive Impairment.</article-title>
            <source>Can J Psychiatry</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>62</volume>
            <issue>3</issue>
            <fpage>161</fpage>
            <page-range>161-169</page-range>
            <pub-id pub-id-type="pmid">28212495</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144392.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Velayudhan</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Neuropsychiatric Symptoms in Mild Cognitive Impairment: A Literature Review.</article-title>
            <source>Dement Geriatr Cogn Disord</source>
            <year>2020</year>
            <volume>49</volume>
            <issue>2</issue>
            <fpage>146</fpage>
            <page-range>146-155</page-range>
            <pub-id pub-id-type="pmid">32289790</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144392.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nasreddine</surname>
                <given-names>ZS</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>B&#x000e9;dirian</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Charbonneau</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Whitehead</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Collin</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Cummings</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Chertkow</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment.</article-title>
            <source>J Am Geriatr Soc</source>
            <year>2005</year>
            <month>Apr</month>
            <volume>53</volume>
            <issue>4</issue>
            <fpage>695</fpage>
            <page-range>695-9</page-range>
            <pub-id pub-id-type="pmid">15817019</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144392.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chun</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Seward</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Patterson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Melton</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>MacDonald-Wicks</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of Available Cognitive Tools Used to Measure Mild Cognitive Decline: A Scoping Review.</article-title>
            <source>Nutrients</source>
            <year>2021</year>
            <month>Nov</month>
            <day>08</day>
            <volume>13</volume>
            <issue>11</issue>
            <pub-id pub-id-type="pmid">34836228</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144392.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Franco-Marina</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-Gonz&#x000e1;lez</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Wagner-Echeagaray</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gallo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ugalde</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>S&#x000e1;nchez-Garc&#x000ed;a</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Espinel-Berm&#x000fa;dez</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ju&#x000e1;rez-Cedillo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-Pe&#x000f1;a</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>The Mini-mental State Examination revisited: ceiling and floor effects after score adjustment for educational level in an aging Mexican population.</article-title>
            <source>Int Psychogeriatr</source>
            <year>2010</year>
            <month>Feb</month>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>72</fpage>
            <page-range>72-81</page-range>
            <pub-id pub-id-type="pmid">19735592</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144392.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yoelin</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Saunders</surname>
                <given-names>NW</given-names>
              </name>
            </person-group>
            <article-title>Score Disparity Between the MMSE and the SLUMS.</article-title>
            <source>Am J Alzheimers Dis Other Demen</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>32</volume>
            <issue>5</issue>
            <fpage>282</fpage>
            <page-range>282-288</page-range>
            <pub-id pub-id-type="pmid">28503934</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144392.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yesavage</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Brink</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Rose</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Lum</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Adey</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Leirer</surname>
                <given-names>VO</given-names>
              </name>
            </person-group>
            <article-title>Development and validation of a geriatric depression screening scale: a preliminary report.</article-title>
            <source>J Psychiatr Res</source>
            <string-date>1982-1983</string-date>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>37</fpage>
            <page-range>37-49</page-range>
            <pub-id pub-id-type="pmid">7183759</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144392.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vega</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Newhouse</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Mild cognitive impairment: diagnosis, longitudinal course, and emerging treatments.</article-title>
            <source>Curr Psychiatry Rep</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>16</volume>
            <issue>10</issue>
            <fpage>490</fpage>
            <pub-id pub-id-type="pmid">25160795</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144392.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hwang</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Longstreth</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Thielke</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Francis</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Carone</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kuller</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Fitzpatrick</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>Longitudinal Changes in Hearing and Visual Impairments and Risk of Dementia in Older Adults in the United States.</article-title>
            <source>JAMA Netw Open</source>
            <year>2022</year>
            <month>May</month>
            <day>02</day>
            <volume>5</volume>
            <issue>5</issue>
            <fpage>e2210734</fpage>
            <pub-id pub-id-type="pmid">35511175</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144392.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mitchell</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Shiri-Feshki</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Rate of progression of mild cognitive impairment to dementia--meta-analysis of 41 robust inception cohort studies.</article-title>
            <source>Acta Psychiatr Scand</source>
            <year>2009</year>
            <month>Apr</month>
            <volume>119</volume>
            <issue>4</issue>
            <fpage>252</fpage>
            <page-range>252-65</page-range>
            <pub-id pub-id-type="pmid">19236314</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144392.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koepsell</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Monsell</surname>
                <given-names>SE</given-names>
              </name>
            </person-group>
            <article-title>Reversion from mild cognitive impairment to normal or near-normal cognition: risk factors and prognosis.</article-title>
            <source>Neurology</source>
            <year>2012</year>
            <month>Oct</month>
            <day>09</day>
            <volume>79</volume>
            <issue>15</issue>
            <fpage>1591</fpage>
            <page-range>1591-8</page-range>
            <pub-id pub-id-type="pmid">23019264</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144392.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elias-Sonnenschein</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Viechtbauer</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Ramakers</surname>
                <given-names>IH</given-names>
              </name>
              <name>
                <surname>Verhey</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>Visser</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Predictive value of APOE-&#x003b5;4 allele for progression from MCI to AD-type dementia: a meta-analysis.</article-title>
            <source>J Neurol Neurosurg Psychiatry</source>
            <year>2011</year>
            <month>Oct</month>
            <volume>82</volume>
            <issue>10</issue>
            <fpage>1149</fpage>
            <page-range>1149-56</page-range>
            <pub-id pub-id-type="pmid">21493755</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144392.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>SPRINT MIND Investigators for the SPRINT Research Group</collab>
              <name>
                <surname>Williamson</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Pajewski</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Auchus</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Bryan</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Chelune</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cheung</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Cleveland</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Coker</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Crowe</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Cushman</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Cutler</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Davatzikos</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Desiderio</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Erus</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fine</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Gaussoin</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hsieh</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Kimmel</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Tamura</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Launer</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Lerner</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Martindale-Adams</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Moy</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Nasrallah</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Nichols</surname>
                <given-names>LO</given-names>
              </name>
              <name>
                <surname>Oparil</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ogrocki</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Rahman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rapp</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Reboussin</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Rocco</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Sachs</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Sink</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Still</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Supiano</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Snyder</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Wadley</surname>
                <given-names>VG</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Weiner</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Whelton</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Woolard</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>CB</given-names>
              </name>
            </person-group>
            <article-title>Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial.</article-title>
            <source>JAMA</source>
            <year>2019</year>
            <month>Feb</month>
            <day>12</day>
            <volume>321</volume>
            <issue>6</issue>
            <fpage>553</fpage>
            <page-range>553-561</page-range>
            <pub-id pub-id-type="pmid">30688979</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144392.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carlsson</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Management of Dementia.</article-title>
            <source>Continuum (Minneap Minn)</source>
            <year>2022</year>
            <month>Jun</month>
            <day>01</day>
            <volume>28</volume>
            <issue>3</issue>
            <fpage>885</fpage>
            <page-range>885-900</page-range>
            <pub-id pub-id-type="pmid">35678408</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
